Gabather AB announced the establishment of a research collaboration with Massachusetts General Hospital to investigate the effect of its drug candidate GT-002 in a preclinical model of Alzheimer's disease. The first stages of the clinical development (single and multiple ascending doses) with GT-002 has recently been successfully completed, paving the way for the development of the drug candidate in a broad range of mental disorders. Gabather has signed an agreement with Massachusetts General Hospital, where Dr. Kastanenka, Assistant Professor of Neurology at Harvard Medical School, and colleagues will investigate the effects of GT-002 in a preclinical model of Alzheimer's disease. The research will be conducted at Massachusetts General Hospital to elucidate the effects of the drug candidate on sleep-dependent brain rhythms, including slow wave activity. This brain rhythm is important for memory consolidation during sleep and has been shown to be disrupted in Alzheimer's disease.